» Articles » PMID: 22981623

First WHO International Reference Panel Containing Hepatitis B Virus Genotypes A-G for Assays of the Viral DNA

Overview
Journal J Clin Virol
Specialty Microbiology
Date 2012 Sep 18
PMID 22981623
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: WHO International Standards (IS) are provided for the calibration and validation of diagnostic and screening assays, e.g. for hepatitis B virus (HBV). HBV forms numerous subgenotypes and the current IS for HBV DNA reflects subgenotype A2.

Objective: A reference panel with the most prevalent subgenotypes should facilitate evaluation of genotype-specific detection efficiencies.

Study Design: 215 HBV positive plasma samples collected worldwide were characterized for HBV markers and sequenced. Fifteen subgenotype A1, A2, B2, B4, C2, D1, D3, E, F2 and G samples were selected for the panel. The lyophilized samples were tested in parallel with the IS in an international collaborative study with 16 laboratories using 13 different nucleic acid amplification techniques (NATs).

Results: Eight of 13 NAT had a HBV DNA detection efficiency which was independent of the genotype and consistent with the IS, while with five assays, certain deviations were noted, particularly with genotype F which was under quantitated or even missed by three assays. The panel was accepted by the WHO as the "1st WHO International Reference Panel for HBV Genotypes for HBV NAT-Based Assays".

Conclusions: The evaluation of HBV DNA assays should include many different genotypes. The WHO Reference Panel is universally available for manufacturers of HBV DNA assays, diagnostic laboratories and control authorities to facilitate standardized validation of HBV genotype specific detection efficiency of both diagnostic (quantitative and qualitative) and screening NAT assays.

Citing Articles

The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines.

Tulaeva I, Lehmann F, Goldmann N, Dubovets A, Trifonova D, Tulaev M Vaccines (Basel). 2024; 12(10).

PMID: 39460290 PMC: 11511130. DOI: 10.3390/vaccines12101123.


Early Dynamics of Hepatitis B Virus (HBV)-DNA and Surface Antigen (HBsAg) in Ramp-Up Phase of Viremia: Implications for Performance Evaluation of Blood Screening Assays.

van Drimmelen H, Lelie N Viruses. 2022; 14(9).

PMID: 36146748 PMC: 9503664. DOI: 10.3390/v14091942.


Mapping the Heterogeneity of Histone Modifications on Hepatitis B Virus DNA Using Liver Needle Biopsies Obtained from Chronically Infected Patients.

Flecken T, Meier M, Skewes-Cox P, Barkan D, Heim M, Wieland S J Virol. 2019; 93(9).

PMID: 30787147 PMC: 6475771. DOI: 10.1128/JVI.02036-18.


Standardization of Nucleic Acid Tests: the Approach of the World Health Organization.

Baylis S, Wallace P, McCulloch E, Niesters H, Nubling C J Clin Microbiol. 2018; 57(1).

PMID: 30257900 PMC: 6322456. DOI: 10.1128/JCM.01056-18.


Determination of hepatitis B phenotype using biochemical and serological markers.

Di Bisceglie A, Lombardero M, Teckman J, Roberts L, Janssen H, Belle S J Viral Hepat. 2016; 24(4):320-329.

PMID: 27917600 PMC: 5733779. DOI: 10.1111/jvh.12643.